menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Improving Outcomes in Patients with RVO: Tailoring Treatment

1.00 credits
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Dr. Carl Danzig, Director of Vitreoretinal Services and Retina Clinical Research of Rand Eye Institute in Deerfield Beach, Florida, and Dr. Arshad Khanani, Clinical Associate Professor at the University of Nevada in Reno, Nevada, will present key data about anti-VEGF therapies for retinal vein occlusion (RVO). Join the discussion on developing treatment protocols that use current therapies most effectively to improve outcomes and individualized treatment protocols for patients who are nonresponsive to first-line therapies and who require chronic treatment for macular edema.

  • Disclosure of Conflicts of Interest

    Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

    Primary Author
    Carl J. Danzig, MD
    Director of Vitreoretinal Services and Retina Clinical Research
    Rand Eye Institute
    Deerfield Beach, Florida
    Affiliate Assistant Professor of Clinical Biomedical Science
    Charles E. Schmidt College of Medicine
    Florida Atlantic University
    Boca Raton, Florida

    Carl J. Danzig, MD: consultant/advisor/speaker: Adverum, Alimera, Genentech, Kodiak Sciences, IvericBio, Regeneron.

    Arshad M. Khanani, MD, MA, FASRS
    Managing Partner
    Director of Clinical Research
    Director of Fellowship
    Sierra Eye Associates
    Clinical Associate Professor
    University of Nevada
    Reno, Nevada

    Arshad M. Khanani, MD, MA, FASRS: consultant: 4D Molecular Therapeutics, AbbVie, Adverum, Aerie, Aldebaran, Allergan, Amgen, Annexin, Annexon, Apellis, Applied Genetics Technologies Corporation, Arrowhead, Ashvattha, Aviceda Therapeutics, Bausch & Lomb, Beacon Therapeutics, Broadwing Bio, Clearside, Exgenesis, EyePoint, Frontera, Genentech, Inc., Gyroscope, iLumen, Iveric Bio, Janssen, Kartos, Kato, Kodiak Sciences, Kriya, Nanoscope, Notal, Novartis, Ocular Therapeutix, Oculis, Ocuphire, OcuTerra, Olives Bio, Opthea, Oxurion, Perfuse, PolyPhotonix, Protagonist, Ray Therapeutics, Recens Medical, Regeneron, Regenxbio, RevOpsis, Roche, Sanofi, Stealth, Thea, Unity, Vanotech, Vial; researcher: 4D Molecular Therapeutics, Adverum, Alexion, Annexon, Apellis, Exegenesis, Genentech, Inc., Gyroscope, Iveric Bio, Kodiak, Neurotech, NGM Bio, Novartis, Ocular Therapeutix, Oculis, OcuTerra, Opthea, Oxular, Oxurion, Regenxbio, Rezolute, Roche, Unity, Vanotech.

    The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

  • Target Audience

    The intended audience for this educational initiative is ophthalmologists, who are clinicians responsible for the ocular evaluation and management of patients with retinal vein occlusion.

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Compare current anti-VEGF therapies for RVO to select the most appropriate therapy for an individual patient
    • Develop treatment protocols in RVO that use current therapies most effectively for a particular patient and that include appropriate follow-ups to improve outcomes in patients with RVO
    • Modify an individualized treatment protocol for patients with RVO who are nonresponsive to first-line therapies and who require chronic treatment for macular edema
  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement
    In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Physician Continuing Medical Education
    CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Goal Statement

    The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Retinal Vein Occlusion (RVO)

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)


    Provided by Clinical Care Options, LLC 

  • Commercial Support

    Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Dr. Carl Danzig, Director of Vitreoretinal Services and Retina Clinical Research of Rand Eye Institute in Deerfield Beach, Florida, and Dr. Arshad Khanani, Clinical Associate Professor at the University of Nevada in Reno, Nevada, will present key data about anti-VEGF therapies for retinal vein occlusion (RVO). Join the discussion on developing treatment protocols that use current therapies most effectively to improve outcomes and individualized treatment protocols for patients who are nonresponsive to first-line therapies and who require chronic treatment for macular edema.

  • Disclosure of Conflicts of Interest

    Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

    Primary Author
    Carl J. Danzig, MD
    Director of Vitreoretinal Services and Retina Clinical Research
    Rand Eye Institute
    Deerfield Beach, Florida
    Affiliate Assistant Professor of Clinical Biomedical Science
    Charles E. Schmidt College of Medicine
    Florida Atlantic University
    Boca Raton, Florida

    Carl J. Danzig, MD: consultant/advisor/speaker: Adverum, Alimera, Genentech, Kodiak Sciences, IvericBio, Regeneron.

    Arshad M. Khanani, MD, MA, FASRS
    Managing Partner
    Director of Clinical Research
    Director of Fellowship
    Sierra Eye Associates
    Clinical Associate Professor
    University of Nevada
    Reno, Nevada

    Arshad M. Khanani, MD, MA, FASRS: consultant: 4D Molecular Therapeutics, AbbVie, Adverum, Aerie, Aldebaran, Allergan, Amgen, Annexin, Annexon, Apellis, Applied Genetics Technologies Corporation, Arrowhead, Ashvattha, Aviceda Therapeutics, Bausch & Lomb, Beacon Therapeutics, Broadwing Bio, Clearside, Exgenesis, EyePoint, Frontera, Genentech, Inc., Gyroscope, iLumen, Iveric Bio, Janssen, Kartos, Kato, Kodiak Sciences, Kriya, Nanoscope, Notal, Novartis, Ocular Therapeutix, Oculis, Ocuphire, OcuTerra, Olives Bio, Opthea, Oxurion, Perfuse, PolyPhotonix, Protagonist, Ray Therapeutics, Recens Medical, Regeneron, Regenxbio, RevOpsis, Roche, Sanofi, Stealth, Thea, Unity, Vanotech, Vial; researcher: 4D Molecular Therapeutics, Adverum, Alexion, Annexon, Apellis, Exegenesis, Genentech, Inc., Gyroscope, Iveric Bio, Kodiak, Neurotech, NGM Bio, Novartis, Ocular Therapeutix, Oculis, OcuTerra, Opthea, Oxular, Oxurion, Regenxbio, Rezolute, Roche, Unity, Vanotech.

    The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

  • Target Audience

    The intended audience for this educational initiative is ophthalmologists, who are clinicians responsible for the ocular evaluation and management of patients with retinal vein occlusion.

  • Learning Objectives

    Upon completion of this activity, participants should be able to:

    • Compare current anti-VEGF therapies for RVO to select the most appropriate therapy for an individual patient
    • Develop treatment protocols in RVO that use current therapies most effectively for a particular patient and that include appropriate follow-ups to improve outcomes in patients with RVO
    • Modify an individualized treatment protocol for patients with RVO who are nonresponsive to first-line therapies and who require chronic treatment for macular edema
  • Accreditation and Credit Designation Statements

    Joint Accreditation Statement
    In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Physician Continuing Medical Education
    CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Goal Statement

    The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Retinal Vein Occlusion (RVO)

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)


    Provided by Clinical Care Options, LLC 

  • Commercial Support

    Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule23 Apr 2024